Search research articles
Contact Us
Filters
Showing results (901-910 of 1,115) with videos related to
Page
of 112
Sort By:
Cancer
|
November 7, 2000
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
S Faderl, H M Kantarjian, E Estey, et al.
Nature Communications
|
October 6, 2011
Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells
Peter J Wen, Shona L Osborne, Mark Zanin, et al.
Plos One
|
December 24, 2011
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia
Carmen D Schweighofer, Kevin R Coombes, Lynn L Barron, et al.
Blood
|
September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Philip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar, et al.
The Journal of Molecular Diagnostics : JMD
|
August 11, 2007
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
Lynne V Abruzzo, Lynn L Barron, Keith Anderson, et al.
Leukemia
|
November 4, 2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
V K Patel, B Lamothe, M L Ayres, et al.
Oncotarget
|
September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
Nitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
Blood
|
May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
Hesham M Amin, Iman Jilani, Elihu H Estey, et al.
Oncotarget
|
March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
Uri Rozovski, David M Harris, Ping Li, et al.
Page
of 112
Search research articles
Search
Showing results (901-910 of 1,115) with videos related to
Sort By:
Page
of 112
Cancer
|
November 7, 2000
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
S Faderl, H M Kantarjian, E Estey, et al.
Nature Communications
|
October 6, 2011
Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells
Peter J Wen, Shona L Osborne, Mark Zanin, et al.
Plos One
|
December 24, 2011
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia
Carmen D Schweighofer, Kevin R Coombes, Lynn L Barron, et al.
Blood
|
September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Philip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
Michael J Keating, Susan O'Brien, Maher Albitar, et al.
The Journal of Molecular Diagnostics : JMD
|
August 11, 2007
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
Lynne V Abruzzo, Lynn L Barron, Keith Anderson, et al.
Leukemia
|
November 4, 2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
V K Patel, B Lamothe, M L Ayres, et al.
Oncotarget
|
September 23, 2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
Nitin Jain, Kumudha Balakrishnan, Alessandra Ferrajoli, et al.
Blood
|
May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
Hesham M Amin, Iman Jilani, Elihu H Estey, et al.
Oncotarget
|
March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
Uri Rozovski, David M Harris, Ping Li, et al.
Page
of 112